SCHEMBL8664052

SCHEMBL8664052

Nc1ncnc2cccc(Cl)c12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.48
PI4K2B Q8TCG2 2/20 0.48
PI4K2A Q9BTU6 2/20 0.48
PI4KB Q9UBF8 2/20 0.48
GAA P10253 1/20 0.47
PARP1 P09874 1/20 0.44
MAP4K4 O95819 4/20 0.42
RET P07949 2/20 0.41
DCPS Q96C86 1/20 0.40
DOT1L Q8TEK3 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
GRIN1 Q05586 3/20 0.39
GRIN2A Q12879 3/20 0.39
ACHE P22303 2/20 0.39
BCHE P06276 1/20 0.38
DHFR P00374 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19826650 0.84 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBMAP4K4
SCHEMBL8808732 0.79 PDE4A (0.52) PARP1PDE4APDE4BPDE4CPDE4D
SCHEMBL8810067 0.76 PARP1 (0.44) PARP1PDE4APDE4BPDE4CPDE4D
SCHEMBL21340231 0.76 PARP1 (0.44) PARP1PDE4APDE4BPDE4CPDE4D
SCHEMBL29937185 0.76 PARP1 (0.44) PARP1PDE4APDE4BPDE4CPDE4D
SCHEMBL17227469 0.76 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBPARP1
SCHEMBL18312022 0.76 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBMAP4K4
SCHEMBL2124702 0.76 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBPARP1
SCHEMBL19826711 0.76 DHFR (0.47) MAP4K4DHFR
SCHEMBL19826675 0.75 SRC (0.48) PI4KAPI4K2BPI4K2API4KBMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311520-B2 Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-04-26 US disclosed
US-20210085656-A1 SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-03-25 US disclosed
US-20190350910-A1 SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-11-21 US disclosed
WO-2018134148-A1 SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-26 WO disclosed
EP-0880505-A1 ACYLATED 4-AMINO- AND 4-HYDRAZINOPYRIMIDINES AND THEIR USE AS PESTICIDES BAYER AG (DE) 1998-12-02 EP disclosed
WO-1997028133-A1 ACYLATED 4-AMINO- AND 4-HYDRAZINOPYRIMIDINES AND THEIR USE AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190350910-A1 SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS MKNK1, MKNK2, MAP4K5 PI4KA 152/4885PI4K2B 176/4885PI4K2A 137/4885
US-20210085656-A1 SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS MKNK1, MKNK2, MAP4K5 PI4KA 151/4885PI4K2B 171/4885PI4K2A 149/4885
US-11311520-B2 Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors MKNK1, MKNK2, MAP4K5 PI4KA 151/4885PI4K2B 171/4885PI4K2A 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.